RASUVO 12.5 MG/0.25 ML AUTOINJ
FDA nonproprietary name: methotrexate
For 1 mL
Pharmacies pay
$574.87 filed
1 × $574.86795 per ML
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-04-01 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$367.06 filed
1 × $367.06071 per ML, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
0.64× estimated
Medicare paid 36% less than pharmacies pay.
Part D averages every strength and form sold under “Rasuvo” / “Methotrexate/PF” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-04-01 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$666.10 estimated
$574.87 + $86.23 (15%) + $5.00 fee per fill = $666.10
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-04-01 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
RASUVO 12.5 MG/0.25 ML AUTOINJ is how the CMS NADAC file names this product. The FDA NDC Directory lists it as methotrexate, under the trade name “Rasuvo”.
FDA gives its dosage form as injection, solution and its route as subcutaneous.
The labeler, the company named on the label, is Medexus Pharma Inc.
FDA’s Established Pharmacologic Class for it is Folate Analog Metabolic Inhibitor.
The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 59137-0515-04.
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $574.87 for 1 mL (1 × $574.86795 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-04-01. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 4, carried forward from the previous file; 5, calculated based on package size.
This NDC’s NADAC was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: it took effect on 2026-04-01. The file is new; the price is not.
What NADAC measures · NADAC explanation codes · Carried-forward prices
The NDC
- 59137-0515-04 · Medexus Pharma Inc. · $574.86795 per ML · eff. 2026-04-01 filed carried forward
Other strengths, forms and brands
13 other products in the NADAC file share the FDA nonproprietary name methotrexate with RASUVO 12.5 MG/0.25 ML AUTOINJ.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| METHOTREXATE 2.5 MG TABLET | $0.15774 per EA filed | $0.157 per EA derived |
| METHOTREXATE 50 MG/2 ML VIAL | $1.23696 to $3.1832 per ML filed | $1.4545 per ML derived |
| METHOTREXATE 250 MG/10 ML VIAL | $0.702 to $3.1832 per ML filed | $1.4545 per ML derived |
| RASUVO 7.5 MG/0.15 ML AUTOINJ | $960.29324 per ML filed | $367.06071 per ML filed |
| RASUVO 10 MG/0.2 ML AUTOINJ | $721.8144 per ML filed | $367.06071 per ML filed |
| RASUVO 12.5 MG/0.25 ML AUTOINJ this page | $574.86795 per ML filed | $367.06071 per ML filed |
| RASUVO 15 MG/0.3 ML AUTOINJ | $480.00227 per ML filed | $367.06071 per ML filed |
| RASUVO 17.5 MG/0.35 ML AUTOINJ | $409.92919 per ML filed | $367.06071 per ML filed |
| RASUVO 20 MG/0.4 ML AUTOINJ | $362.2851 per ML filed | $367.06071 per ML filed |
| RASUVO 25 MG/0.5 ML AUTOINJ | $289.365 per ML filed | $367.06071 per ML filed |
| TREXALL 5 MG TABLET | $24.08844 per EA filed | $41.73652 per EA filed |
| TREXALL 7.5 MG TABLET | $36.20914 per EA filed | $41.73652 per EA filed |
| TREXALL 10 MG TABLET | $48.13525 per EA filed | $41.73652 per EA filed |
| XATMEP 2.5 MG/ML ORAL SOLUTION | $21.76353 per ML filed | $19.76312 per ML filed |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. between 2026-01-01 and 2026-09-23 (4 dates) · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)
Compared with its class
Its NADAC price is $574.86795 per ML filed.
Of the 9 other products in FDA’s Folate Analog Metabolic Inhibitor class priced per ML, 2 have a higher middle NADAC price and 7 a lower one. The one in the middle is RASUVO 20 MG/0.4 ML AUTOINJ, at $362.2851 per ML filed (eff. 2026-09-23).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-04-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
Medicare Part D paid $367.06 for 1 mL, at an average of $367.06071 per ML in 2024 (2024-01-01 to 2024-12-31) for “Rasuvo” and “Methotrexate/PF”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 31,894 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 1 mL? Is it lower than what I would pay through my insurance?
- How much is in the package I am getting? This page uses 1 mL; your package may hold a different amount.
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for RASUVO 12.5 MG/0.25 ML AUTOINJ labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Rasuvo / Methotrexate/PF: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's ML. Joined on brand name.
- Why does this page start at 1 mL?
- NADAC prices this product per ML. The FDA NDC Directory’s package description gives 1 mL in one package for this product’s NDC (“4 PACKAGE in 1 CARTON (59137-515-04) / .25 mL in 1 PACKAGE (59137-515-00)”), so the card starts at one package: 1 ML. Change it to match your prescription.